Migraine: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CGRP 19
• HMGB1 0
• NOTCH3 0
• GLP-1 0
• MAPK 0
• PI3K 0
• IL-17 0
• IL-6 1
• TNF 1
• PPAR 0
• TREM2 0
• COX-2 0
• IL-4 0
• STING 0
• AKT 0
• AMPK 0
• AQP4 0
• ERK 0
• GIP 0
• GPX4 0
• HIF-1 0
• IL-1 1
• mTOR 0
• NLRP3 0
• NMDA 0
• PD-1 0
• SCN1A 0
• SCN2A 0
• STAT3 0
• VEGF 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-JU-IA

  closed-loop IMPlantable tHerapeutic neurOmodulation systems enabled by advanced micRoelectronics and Innovative pAckaging (IMPHORIA)

  Salvia Bioelectronics Bv· Eindhoven, Netherlands· EU contribution €4,567,844· until Apr 2029· 5 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Hospital@Home: Person-centered Digital Transformation for Integrated Home Care (HospitalAtHome)

  Erasmus Universitair Medisch Centrum Rotterdam· Rotterdam, Netherlands· EU contribution €14,179,766· until Dec 2030· 8 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Combinatorial use of cannabidiol and the serine hydrolase inhibitor AKU-005 to enhance endocannabinoids for treatment of migraine (Migraine cannabinoid)

  King's College London· London, United Kingdom· EU contribution €454,103· until Jun 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  INNOVATIVE SOLUTION OF ELECTRO-FOCUS EYEGLASSES (I-SEE)

  Laclaree· Lyon, France· EU contribution €2,499,999· until Nov 2026

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  A mechanism-based approach to the prevention of chronic pain and its comorbid mental disorders (MECHPAIN)

  Zentralinstitut Fuer Seelische Gesundheit· Mannheim, Germany· EU contribution €2,424,481· until Sept 2029

  The disease is named only in the funder's project summary, not in the title.

5 of 6 running projects, newest first. Listed amounts together: €26.6m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 7
• Mendelian Randomization Analysis 33
• Gene Expression Profiling 8
• Sequence Analysis, RNA 2
• Exome Sequencing 5
• Proteomics 6
• Metabolomics 6
• Mass Spectrometry 1
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 136
• Machine Learning 32
• Deep Learning 1
• Cohort Studies 82
• Genome-Wide Association Study 40

• Integrating Metabolomics and Machine Learning Reveals Metabolic Signatures and Candidate Biomarkers for Vestibular Migraine.

  J Proteome Res, Oct 2026

• Untargeted and Targeted Metabolomics Reveal the Regulatory Mechanisms of the Chuanxiong-Baizhi Herb Pair in Treating Migraine.

  Rapid Commun Mass Spectrom, Aug 2026

• Metabolomic insights into migraine: mechanisms and biomarkers from in vivo and clinical studies.

  Metab Brain Dis, Jul 2026

• Integrated metabolomics and transcriptomics analysis to reveal the mechanism of Xuefu Zhuyu Decoction in the treatment of nitroglycerin-induced chronic migraine.

  J Pharm Biomed Anal, Apr 2026

• Spatial metabolomics combined with MALDI-MSI unveils gut-brain axis mechanisms of angelica dahurica radix in migraine rats.

  Phytomedicine, Jan 2026

• Integrated analysis of blood-absorbed components, metabolomics, and transcriptomics reveals Tianshu Capsule's effective components and mechanisms.

  Phytomedicine, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.